What FDNA does

FDNA is a Boston-headquartered, Delaware-incorporated healthcare AI company (also listed with operational headquarters in Atlanta, GA) that develops facial dysmorphology and multi-modal phenotype analysis technology for detecting developmental delays, genetic disorders, and rare diseases. Its core product, Face2Gene, is an AI-powered phenotypic analysis tool used by geneticists, pediatric specialists, and other clinicians; the consumer-facing Family Health Checker app extends the same technology to parents for self-assessment and specialist routing. Underlying the products is a proprietary multi-modal algorithm framework that integrates image analysis, natural language processing, video analysis, voice analysis, and structured symptom data through 10+ named algorithms including Deep Gestalt®, Gestalt Matcher™, D-Score™, A-Score™, Feature Match™, Feature Extraction, Heat Maps, Focus Assessment, Clinical Notes Analyzer, and Symptom Assessment, all mapping outputs to Human Phenotype Ontology (HPO) terms.

The company generates revenue through four documented streams: subscription access to Face2Gene for healthcare professionals, targeted advertising by pharmaceutical companies on the Family Health Checker app, subscription-based data and patient-recruitment services sold to Contract Research Organizations, and AI-driven patient engagement and decision support tools sold to health services. Pricing for healthcare professionals, pharma, CROs, and health systems is not publicly disclosed and follows an enterprise inquiry-led sales motion; the consumer app is free. FDNA serves a diversified customer set spanning parents/patients, pediatric and genetic specialists, pharma, CROs, researchers, and health services, with the platform deployed across 10,000+ medical centers in 130+ countries and supported by 100+ peer-reviewed publications. FDNA is privately held with 11–50 employees, no disclosed funding rounds, no parent company, and a Scientific Advisory Board chaired by Michael Hayden with Karen Gripp as Chief Medical Officer.

Name

FDNA

Legal name

FDNA Inc.

Website

https://fdna.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

FDNA is an AI-native healthcare technology company that builds multi-modal phenotype analysis algorithms (Deep Gestalt, Gestalt Matcher) for early detection of developmental and genetic disorders, serving clinicians via Face2Gene, parents via a free Family Health Checker app, and pharma and CROs through data and patient-recruitment services across 10,000+ medical centers in 130+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Healthcare Professional Tools (Face2Gene): Face2Gene provides advanced AI-powered phenotypic analysis for genetic specialists. Healthcare professionals pay for access to decision support tools and comprehensive genetic databases. The platform enhances patient engagement and streamlines the diagnostic process.
2. Pharma Company Advertising: FDNA enables pharmaceutical companies to promote their medications on the Family Health Checker app platform based on patient symptoms and AI analysis, ensuring targeted advertising to relevant audiences.
3. CRO Data Access & Recruitment: FDNA provides CROs with access to a vast network of patients, healthcare providers, and a comprehensive data clearing house. AI-based analysis tools enhance patient recruitment for clinical trials.
4. Health Services Patient Engagement: Health services pay for AI-based patient engagement solutions, decision support tools, and care management tools. The platform helps them connect with broader patient audiences and improve diagnostic capabilities.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

FDNA develops AI-powered facial analysis and multi-modal phenotyping software that helps healthcare professionals detect and diagnose developmental, genetic, and rare disorders. Its flagship Face2Gene platform uses proprietary algorithms (Deep Gestalt, Gestalt Matcher, D-Score, A-Score, etc.) to map patient images and clinical features to potential syndromes, while the free Family Health Checker app lets parents run AI-based developmental assessments. The company also operates a data clearing house and provides vertical-specific services for pharmaceutical companies, contract research organizations (CROs), and researchers.

Product overview

FDNA is an AI-powered healthcare technology company offering a multi-product portfolio centered on early detection and diagnosis of developmental and genetic disorders. The core offerings include Face2Gene (AI phenotypic analysis for healthcare professionals), the Family Health Checker App (AI-powered assessment tool for parents), and the FDNA Healthcare Professional Tools (decision support and patient engagement suite). These products integrate across multiple modalities including facial image analysis, symptom assessment, NLP, video analysis, and voice analysis. The platform is used in over 10,000 medical centers across 130+ countries and is backed by a multi-modal AI framework comprising algorithms including Deep Gestalt, Gestalt Matcher, Feature Extraction, Heat Maps, Focus Assessment, Feature Match, Clinical Notes Analyzer, Symptom Assessment, D-Score, and A-Score. The platform serves diverse stakeholders including parents, healthcare providers (pediatric specialists, geneticists, health services), pharmaceutical companies, CROs, and researchers.

Differentiator

Problem solved

Functional benefit

Brands

• Face2Gene: AI-powered phenotypic analysis tool for genetic specialists to expedite diagnosis of rare diseases
• Family Health Checker
• Deep Gestalt®
• Gestalt Matcher™
• D-Score™
• A-Score™
• Feature Match™

Products and services

• Face2Gene AI-powered phenotypic analysis platform used by licensed healthcare professionals (geneticists, pediatric specialists) to analyze facial images and patient features, surface potential genetic syndromes, and support diagnostic workflows for developmental and rare diseases. Outputs are non-diagnostic and intended for clinical decision support.
• Family Health Checker App Free AI-powered mobile and web app for parents and patients to assess a child's developmental concerns, run symptom and image-based assessments, and receive reports to share with healthcare providers. Currently available only in the US and serves as a digital front door for FDNA's healthcare provider and pharma partners.
• FDNA Data Clearing House Interoperability and data platform offering streamlined connectivity between healthcare providers, patients, pharma companies, therapy services, and contract research organizations, leveraging FDNA's phenotypic database for matching, recruitment, and research use cases.
• FDNA for Pharma Companies Service offering for pharmaceutical companies that combines targeted drug promotion on the Family Health Checker app (based on patient symptoms and AI analysis) with access to FDNA's patient and provider network, AI-driven drug discovery inputs, and clinical trial support.
• FDNA for CROs Service for contract research organizations providing AI-based patient recruitment, access to FDNA's diverse phenotypic patient and provider network, and analytical tools to expand clinical trial portfolios, especially for rare and genetic disease studies.
• FDNA for Researchers Service for academic and translational researchers providing AI-driven analysis tools, access to FDNA's comprehensive genetic and phenotypic database, precise phenotyping, and deep learning algorithms to support genetic and rare disease research projects.

Quantifiable outcome

• Used in 10,000+ medical centers worldwide
• +3 more outcomes

Segments7 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature10 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Natera: Clinical genetic testing company spanning reproductive health, oncology, and rare disease with substantial hospital channel presence. Comparable on clinical genomics customer overlap, though Natera is a much larger testing-services incumbent rather than a phenotype-AI specialist.
• DeepHealth (RadNet): Medical imaging AI subsidiary of RadNet, applying computer vision and deep learning across radiology workflows. Comparable on the medical imaging AI technology stack, but focused on radiology rather than pediatric phenotypic analysis, and operates within a much larger imaging services platform.
• Invitae: Large clinical genetic testing laboratory serving hospitals, clinicians, and patients across hereditary disease areas. Overlapping clinical geneticist customer base and rare disease use cases, but operates a lab-based testing model rather than AI phenotypic decision support, making FDNA a complementary or upstream tool.
• Foundation Medicine: Molecular diagnostics company (Roche subsidiary) providing genomic profiling for oncology with biopharma data partnerships. Comparable on the biopharma data clearing house and clinical genomics customer overlap, though focused on oncology rather than rare genetic disease and operated at substantially greater scale.
• Tempus Labs: AI-driven precision medicine company combining multi-modal data (clinical, molecular, imaging) for oncology and broader disease areas. Comparable on multi-modal AI infrastructure and pharma/CRO data partnerships, but Tempus is a much broader, well-capitalized player focused primarily on oncology rather than pediatric rare disease.

Emerging players

• Rady Children's Institute for Genomic Medicine: Pediatric genomics program delivering rapid whole genome sequencing for critically ill newborns with suspected genetic disease. Overlapping rare pediatric genetic disease mission and clinical user base, though structured as a research-driven institute rather than a commercial SaaS platform.
• Genomics plc: AI-driven genomics company applying machine learning to large-scale genetic and phenotypic data for drug discovery and clinical insight. Comparable on AI-over-phenotype-and-genomics positioning and biopharma customer overlap, but with research and pharma focus rather than point-of-care clinician decision support.

Direct peers

• SOPHiA GENETICS: AI-driven clinical genomics analysis platform serving hospitals and clinical geneticists worldwide with a SaaS subscription model. Closest direct peer—same customer base (clinical geneticists, hospital labs), same AI-decision-support category, and similar revenue motion around rare disease and hereditary oncology workflows.
• Variantyx: Whole genome and exome sequencing diagnostics company focused on rare disease and neurological disorder diagnosis. Comparable on rare disease clinical customer base, though Variantyx operates as a sequencing lab whereas FDNA provides AI decision support upstream and alongside testing.
• Fabric Genomics: AI-based genomic interpretation platform purpose-built for rare disease variant prioritization, used by clinical labs and pediatric hospitals. Directly comparable on the rare disease AI decision-support category, although focused on sequence variant analysis rather than FDNA's phenotypic image analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

• Xx.com/FDNA
• LinkedInlinkedin.com/company/fdna

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FDNA